Drug Profile

Research programme: anabolic bone therapeutics - Acceleron

Alternative Names: ACE-05X; ACE-661

Latest Information Update: 01 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Acceleron Pharma
Class Proteins
Mechanism of Action Bone resorption factor inhibitors; Osteogenesis stimulants; Transforming growth factor beta inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

22 Nov 2021 Acceleron Pharma has been acquired by Merck & Co
16 Jul 2016 No recent reports of development identified for preclinical development in Bone-resorption in USA
21 Feb 2008 Acceleron Pharma and Celgene Corporation enter into an option agreement for certain discovery stage bone loss programmes

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com